Laidlaw Capital Markets is pleased to announce today’s pricing of Soleno Therapeutics (SLNO). Laidlaw served as Co-Manager for the $15,400,000 Follow-On Offering.
This link is provided as a service to you, and will take you to a third party site not affiliated with this site. We are not responsible for the content and do not guarantee the accuracy of any information or material contained therein Laidlaw & Company provides links to web sites of other organizations in order to provide visitors with certain information. A link does not constitute an endorsement of content, viewpoint, policies, products or services of that web site. Once you link to another web site not maintained by Laidlaw & Company, you are subject to the terms and conditions of that web site, including but not limited to its privacy policy.
Click the link above to continue or CANCEL
